BioCentury | Oct 10, 1994
Finance

Life on the dole from D. Blech

...we go. They tell us the technology is great, but these are not normal circumstances." Parnassus Pharmaceuticals Inc....
...program focused on inhibitors of the CD28-B7 interaction for transplant rejection and chronic autoimmune diseases. Parnassus...
...Perkins, Caufield & Byers, but ultimately decided to work with Blech. During the funding search, Parnassus...
Items per page:
1 - 1 of 1
BioCentury | Oct 10, 1994
Finance

Life on the dole from D. Blech

...we go. They tell us the technology is great, but these are not normal circumstances." Parnassus Pharmaceuticals Inc....
...program focused on inhibitors of the CD28-B7 interaction for transplant rejection and chronic autoimmune diseases. Parnassus...
...Perkins, Caufield & Byers, but ultimately decided to work with Blech. During the funding search, Parnassus...
Items per page:
1 - 1 of 1